Effects of Endothelial Nitric Oxide Synthase,Interleukin-6 Gene Polymorphisms and Asymmetric Dimethylarginine Levels on Risk Factors and Lesion Sites in Peripheral Artery Disease
Free accessResearch articleFirst published online August, 2009
Effects of Endothelial Nitric Oxide Synthase,Interleukin-6 Gene Polymorphisms and Asymmetric Dimethylarginine Levels on Risk Factors and Lesion Sites in Peripheral Artery Disease
This study investigated risk factors for atherosclerosis and their relationship with lesion sites. Patients (n = 160) with peripheral artery disease (PAD) completed a questionnaire regarding risk factors for PAD. Endothelial nitric oxide synthase (eNOS) and interleukin (IL)-6 gene polymorphisms and asymmetric dimethylarginine (ADMA) levels were measured. Patients with coronary artery disease had significantly higher ratios of eNOS T/C and C/C genotypes, which include the C allele, than the T/T genotype. The IL-6 gene polymorphism distribution ratios for patients with over four risk factors were significantly different compared with other patients, with a higher rate of the C/C genotype. ADMA levels did not show any significant relationship to risk factors or polymorphism. Levels were, however, slightly higher in femoral lesion sites. The results support a model in which the C/C genotype of eNOS and IL-6 gene polymorphisms promote PAD development. The eNOS C/C genotype may have an independent effect, whereas the effects of the IL-6 C/C genotype are seen in conjunction with other risk factors.
ChapmanCMBeilbyJPHumphriesSE: Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population. Eur Heart J2003; 24: 1494–1499.
2.
GhilardiGBiondiMLDeMontiM: Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthase gene. Clin Chem2002; 48: 989–993.
3.
TarnowLHovindPStehouwerCDA: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care2004; 27: 765–769.
4.
JanssensSPShimouchiAQuetermousT: Cloning and expression of cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem1992; 267: 14519–14522.
5.
VitaJATreasureCBNabelEG: Coronary vasomotor response to acetylcholine relates to risk factors for coronary arterial disease. Circulation1990; 81: 491–497.
6.
HuangPLHuangZMashimoH: Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature1995; 377: 239–242.
7.
VallancePLeoneACalverA: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet1992; 339: 572–575.
8.
VallancePLeiperJ: Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol2004; 24: 1023–1030.
9.
BögerRHRonES: L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev2005; 10: 14–23.
10.
ValkonenVPPäiväHSalonenJT: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet2001; 358: 2127–2128.
11.
LuTMDingYALinSJ: Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J2003; 24: 1912–1919.
12.
BaeSWStühlingerMCYooHS: Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol2005; 95: 729–733.
13.
McBrideAESilverPA: State of the arg: Protein methylation at arginine comes of age. Cell2001; 106: 5–8.
14.
BögerRHSydowKBorlakJ: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosyl-methionine-dependent methyltransferases. Circ Res2000; 87: 99–105.
15.
OgawaTKimotoMSasaokaK: Purification and properties of a new enzyme, NG, NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem1989; 264: 10205–10209.
16.
BögerRH: When the endothelium cannot say ‘NO’ anymore. ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease. Eur Heart J2003; 24: 1901–1902.
17.
DalmonJLaurentMCourtoisG: The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol1993; 13: 1183–1193.
18.
VickersMAGreenFRTerryC: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res2002; 53: 1029–1034.
19.
LatkovskisGLicisNKalninsU: C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet2004; 31: 207–213.
20.
LibraMSignorelliSSBevelacquaY: Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol2006; 59: 211–215.
21.
JohnSWWeitznerGRozenR: A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res1991; 19: 408.
22.
Fernández-RealJMBrochMVendrellJ: Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes2000; 49: 517–520.
23.
MillerSADykesDDPoleskyHF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res1988; 16: 1215.
24.
SurdackiANowickiMSandmannJ: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol1999; 33: 652–658.
25.
FujiwaraNOsanaiTKamadaT: Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: Modulation of nitric oxide synthesis by salt intake. Circulation2000; 101: 856–861.
26.
AbbasiFAsagmiTCookeJP: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol2001; 88: 1201–1203.
27.
StühlingerMCOkaRKGrafEE: Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. Circulation2003; 108: 933–938.
28.
SchlaichMPParnellMMAhlersBA: Impaired l-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation2004; 110: 3680–3686.
29.
BurzottaFIacovielloLDi CastelnuovoA: Relation of the −174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol2001; 88: 1125–1128.
30.
GiacconiRCiprianoCAlbaneseF: The–174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing. Exp Gerontol2004; 39: 621–628.
31.
RauramaaRVäisänenSBLuongLA: Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid arterial atherosclerosis. Arterioscler Thromb Vasc Biol2000; 20: 2657–2662.
32.
FaraciFMSigmundCDSheselyEG: Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase. Am J Physiol1998; 274 (2 Pt 2): H564–H570.
33.
ChataigneauTFélétouMHuangPL: Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol1999; 126: 219–226.
34.
NakayamaMYasueHYoshimuraM: T–786→ C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol2000; 86: 628–634.
35.
MasudaHGotoMTamaokiS: Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol1999; 126: 211–218.
36.
NauckMWinkelmannBRHoffmannMM: The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: No association with plasma interleukin-6, coronary arterial disease, and myocardial infarction. J Mol Med2002; 80: 507–513.
